Skip to main content

Table 1 Clinical-pathological parameters of patients with prostate cancer and non-malignant prostate disease

From: Alterations of global histone H4K20 methylation during prostate carcinogenesis

  PCA (n = 113) BPH (n = 17) normal (n = 6)
serum PSA    
   < 4 ng/ml 9 (7.9%) 0 (0.0%) 0 (0.0%)
   4-10 ng/ml 48 (42.5%) 2 (11.7%) 0 (0.0%)
   > 10 ng/ml 48 (42.5%) 2 (11.7%) 0 (0.0%)
   n.a. 8 (7.1%) 13 (76.5%) 6 (100%)
digital rectal examination    
   normal 51 (45.1%)   
   suspicious 50 (44.2%)   
   n.a. 12 (10.6%)   
pathological stage    
   pT2 61 (54.0%)   
   pT3a 33 (29.2%)   
   pT3b 16 (14.1%)   
   pT4 3 (2.6%)   
   seminal vesicle infiltration 18 (15.8%)   
   lymph node metastasis 9 (7.9%)   
Gleason Score    
   < 7 48 (42.5%)   
   3 + 4 = 7 11 (9.8%)   
   4 + 3 = 7 11 (9.8%)   
   8-10 43 (38.0%)   
  1. n.a., not available; PCA, prostate cancer; BPH, benign prostate hyperplasia